ArticleParasites & vectors2026
Efficacy of lotilaner (Credelio
Article in Parasites & vectors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCanine babesiosis is a clinically significant tick-borne disease, caused by different Babesia species. Babesia canis, one of the most important and widespread species in Europe, is transmitted by Dermacentor reticulatus ticks and can cause potentially fatal canine disease. Prevention of pathogen transmission can be achieved by regular tick control and prophylaxis. The present study evaluated the efficacy of a single oral application of lotilaner (Credelio
methodsTwenty-four B. canis-negative dogs were allocated to three groups (n = 8 each). The two treatment groups were treated once orally with Credelio either on Day 0 or 23, while the negative control was sham-dosed accordingly. All dogs were challenged with B. canis-infected D. reticulatus on Day 28, i.e., 28- or 5-days post-treatment (p.t.), for the lotilaner-treated groups. Tick efficacy was assessed by in situ tick counts 24 and 48 h after infestation (Days 29 and 30) and final tick counts and removals 120 h after infestation (Day 33). Clinical examinations, hematology (blood smear), serology (IFAT) and blood PCR were performed in all dogs systematically and in case of suspected clinical babesiosis.
resultsA single oral treatment with Credelio 28 or 5 days prior to infestation with B. canis-infected D. reticulatus resulted in 100% blocking efficacy against B. canis transmission, as compared to untreated dogs (p < 0.001). The lotilaner-treated dogs were healthy and did not show any clinical or hematological signs of B. canis infection. No treated dog seroconverted or showed a positive PCR. The untreated negative controls tested positive for B. canis from Day 35 onward. All negative controls developed B. canis infection by Day 36 (clinical signs, blood smear, PCR). From Day 43 onward, positive IFAT was also observed. Lotilaner administered on Day 0 or Day 23 demonstrated tick efficacy of 99.7 and 100%, respectively (Day 33).
conclusionsThis study confirmed a single oral application of lotilaner chewable tablets was highly effective (100%) against D. reticulatus, blocking the transmission of B. canis to dogs at the beginning as well as at the end of the monthly treatment interval of Credelio.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.